# Refactor

> Refactor is a VC fund in Burlingame backing Health Care and Biotechnology. See 110 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Burlingame, United States
- Total investments: 110
- Last investment: Feb 2026
- Lead investor: 17%
- Last fund: Jun 2024
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/refactor-capital/
- X (Twitter): https://www.twitter.com/refactor
- Website: http://www.refactor.com
- Facebook: https://www.facebook.com/refactorcapital

Refactor is a seed-stage VC firm investing in bio, climate, and hard tech startups run by Zal Bilimoria. Zal was a partner at a16z and PM for a decade at Google, Netflix, and LinkedIn. He led the seed rounds of Solugen, Astranis, and many other hard tech startups. He is the only decision maker at the firm, writing $1-2M checks in pre-seed and seedrounds.

## Contacts

5 contacts available for Refactor. Shizune tracks 1 team members at Refactor. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/refactor-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2.7M–$11M |
| Series A | $10M–$34M |
| Series B | $16M–$103M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 32 | 29% |
| Biotechnology | 28 | 25% |
| Medical | 12 | 11% |
| Artificial Intelligence | 10 | 9% |
| Software | 8 | 7% |

109 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 55 | 50% |
| Series A | 24 | 22% |
| Series B | 7 | 6% |
| Pre-Seed | 4 | 4% |
| Series C | 4 | 4% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 67 | 61% |
| United Kingdom | 2 | 2% |
| New Zealand | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Zal Bilimoria | Founding Partner | 23 | https://shizune.co/investors/profile/zal-bilimoria |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| The Biological Computing | Biological Black Box integrates biological neurons with artificial neural networks to develop a living computer. | $25M | Seed | Feb 12, 2026 |  |
| Berkeley Yeast | Berkeley Yeast engineers yeast strains to help brewers create beers that are delicious and sustainable. The company was founded by Berkeley PhDs in 2017. Its headquarters is based in Oakland, California. They consume around the world, from regional specialties to staples used by billions of people daily. This includes beer and wine, but also bread,cheese, vinegar, soy sauce, fish sauce, kombucha, miso, chocolate, and others. The list is long and reveals a broad and exciting horizon. |  | Series A | Dec 23, 2025 |  |
| Pila Energy | Pila Energy develops innovative battery systems and software to provide energy security and energy management for homes and businesses. The company offers a plug-and-play battery solution for renters and homeowners alike that installs via standard outlets, providing backup power, energy savings, and intelligent load management without complexinstallation overhead. Pila’s system integrates advanced battery storage, power electronics, and mesh networking software to optimize energy use and enhance resilience. Pila Energy was founded in 2024 and is headquartered in San Francisco, CA. | $4M | Seed | Oct 21, 2025 |  |
| Nome Bio | Nome is the Operating System for Personalized Therapies™. Where traditional pharmaceutical infrastructure was built for mass-market drugs, Nome provides the coordination layer that rare disease programs require: AI-driven genomic assessment, regulatory navigation, researcher and manufacturer matching, and end-to-end program management — all in oneplatform.Nome serves as a tech-enabled service company sitting between the patient and the clinic. For a patient or family, Nome delivers a free therapy eligibility assessment in 1–2 weeks, followed by an execution-ready action plan. For clinicians and foundations, Nome functions as an intelligent scientific program manager — handling the orchestration complexity that has historically made personalized drug development inaccessible outside of elite academic medical centers.The platform is modality-agnostic, with current focus on antisense oligonucleotides and gene therapies. Nome also operates as a preclinical CRO, offering target design, toxicology studies, and pre-clinical manufacturing services for rare genetic diseases.Founded by Steven Ringel — a rare disease patient, former Sema4, GeneDx, and Tempus operator, and founder of the Kizuna Foundation (foundation to develop retinal gene therapies) — Nome emerged from stealth in October 2025 backed by Twelve Below, Refactor Capital, and Inflect Health. | $2.7M | Seed | Oct 15, 2025 |  |
| Pilgrim | Pioneering a biologically enhanced future for humanity. | $4.3M | Seed | Aug 06, 2025 |  |
| Remedy Scientific | Remedy Scientific is a pioneering environmental remediation technology firm. It strives to revolutionize how the world combats environmental contamination. The company focuses on restoring contaminated land using advanced technology, including AI and precise sensors, to return sites to productive use. | $11M | Seed | Apr 09, 2025 |  |
| Pilgrim | Pioneering a biologically enhanced future for humanity. | $3.3M | Pre-Seed | Mar 17, 2025 |  |
| Pilgrim | Pioneering a biologically enhanced future for humanity. |  | Seed | Mar 17, 2025 |  |
| Causal Labs | Causal Labs provides AI physics models to predict and control the weather. | $6M | Seed | Mar 12, 2025 |  |
| MIIST Therapeutics | MIIST Therapeutics is a pulmonary drug delivery system and digital platform that enhances the science of inhaled drugs. In order to reduce the excessive quantity of death and sickness brought on by tobacco use, MIIST is actively developing technology that will be used as a smoking cessation therapy. | $7M | Seed | Feb 05, 2025 |  |

10 of 110 investments shown.

## Co-investors
- [Fifty Years](https://shizune.co/investors/profile/fifty-years) — VC Fund, 20 deals together
- [Y Combinator](https://shizune.co/investors/profile/y-combinator) — VC Fund, 18 deals together
- [Cantos](https://shizune.co/investors/profile/cantos-ventures) — VC Fund, 12 deals together
- [BoxGroup](https://shizune.co/investors/profile/boxgroup) — VC Fund, 9 deals together
- [Baillie Gifford](https://shizune.co/investors/profile/baillie-gifford) — VC Fund, 8 deals together
- [SV Angel](https://shizune.co/investors/profile/sv-angel) — VC Fund, 8 deals together

## Similar investors

### Similar industry
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Health Care Investors in United States](https://shizune.co/investors/health-care-investors-united-states)
- [Health Care VC Funds in United States](https://shizune.co/investors/health-care-vc-funds-united-states)
- [Biotech Investors in United States](https://shizune.co/investors/biotech-investors-united-states)
- [Biotech VC Funds in United States](https://shizune.co/investors/biotech-vc-funds-united-states)
- [Life Science Investors in United States](https://shizune.co/investors/life-science-investors-united-states)
- [Life Science VC Funds in United States](https://shizune.co/investors/life-science-vc-funds-united-states)

## FAQ

### What does Refactor invest in?

Refactor invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Series A stage. Most of the 110 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Refactor's check size?

Refactor typically joins rounds of $2.7M–$11M at Seed, $10M–$34M at Series A and $16M–$103M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Refactor participates in.

### How do I contact Refactor?

Public channels for Refactor include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Refactor?

The team at Refactor includes Zal Bilimoria (Founding Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co